Cargando…
Cancer wars: natural products strike back
Natural products have historically been a mainstay source of anticancer drugs, but in the 90's they fell out of favor in pharmaceutical companies with the emergence of targeted therapies, which rely on antibodies or small synthetic molecules identified by high throughput screening. Although tar...
Autores principales: | Basmadjian, Christine, Zhao, Qian, Bentouhami, Embarek, Djehal, Amel, Nebigil, Canan G., Johnson, Roger A., Serova, Maria, de Gramont, Armand, Faivre, Sandrine, Raymond, Eric, Désaubry, Laurent G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013484/ https://www.ncbi.nlm.nih.gov/pubmed/24822174 http://dx.doi.org/10.3389/fchem.2014.00020 |
Ejemplares similares
-
SFPH proteins as therapeutic targets for a myriad of diseases
por: Wang, Dong, et al.
Publicado: (2020) -
Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018) -
FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity
por: Qureshi, Rehana, et al.
Publicado: (2015) -
Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
por: Audebrand, Anais, et al.
Publicado: (2020) -
Staph wars: the antibiotic pipeline strikes back
por: Douglas, Edward J.A., et al.
Publicado: (2023)